Shennon Biotechnologies (ShennonBio), a biotech company using a proprietary single cell platform to create more effective immunotherapies, announced the close of a $13M oversubscribed seed financing round led by DCVC, with participation from Foundation Capital, AV8 and angel investors.

Founded in 2021, ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level within a few hours, enabling the identification of TCR or antibody targets to develop more precise and effective immunotherapies.